Oncology
 |
|
11 december 2019 07:02:49 |
| Real-world incidence and cost of pneumonitis post-chemoradiotherapy for Stage III non-small-cell lung cancer (Future Oncology) |
|
Tweet Future Oncology, Volume 16, Issue 1, Page 4303-4313, January 2020. |
| 252 viewsCategory: Oncology |
 Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer (Future Oncology)Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study (Future Oncology) 
|
| blog comments powered by Disqus |
MyJournals.org
The latest issues of all your favorite science journals on one page
The latest issues of all your favorite science journals on one page
